<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">docru</journal-id><journal-title-group><journal-title xml:lang="ru">Доктор.Ру</journal-title><trans-title-group xml:lang="en"><trans-title>Title</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-2378</issn><issn pub-type="epub">2713-2994</issn><publisher><publisher-name>ООО "ГК "РУСМЕДИКАЛ"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31550/1727-2378-2022-21-1-54-58</article-id><article-id custom-type="elpub" pub-id-type="custom">docru-141</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГИНЕКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GYNECOLOGY</subject></subj-group></article-categories><title-group><article-title>Цервикальные интраэпиталиальные неоплазии II степени: эффективность противовирусной терапии</article-title><trans-title-group xml:lang="en"><trans-title>Cervical Stage II Intraepithelial Neoplasia: Antivirals Efficacy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9094-8772</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виноградова</surname><given-names>О. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinogradova</surname><given-names>O. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виноградова Ольга Павловна — д. м. н., профессор кафедры акушерства и гинекологии </p><p>440060, г. Пенза, ул. Стасова, д. 8А </p></bio><bio xml:lang="en"><p>8A Stasov St., Penza, 440060</p></bio><email xlink:type="simple">o_vinogradova69@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2207-7039</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреева</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreeva</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андреева Наталья Анатольевна — к. м. н., доцент кафедры акушерства и гинекологии </p><p>430005, г. Саранск, ул. Большевистская, д. 68</p></bio><bio xml:lang="en"><p>68 Bolshevistskaya Str., Saransk, 430005 </p></bio><email xlink:type="simple">andreeva_77@list.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4996-026X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Артёмова</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Artemova</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Артёмова Ольга Игоревна — к. м. н., доцент кафедры акушерства и гинекологии </p><p>440026, г. Пенза, ул. Красная, д. 40 </p></bio><bio xml:lang="en"><p>40 Krasnaya St., Penza, 440026</p></bio><email xlink:type="simple">artyomovaolg@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3961-809X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Епифанова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Epifanova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Епифанова Ольга Викторовна — ассистент кафедры акушерства и гинекологии  </p><p>440060, г. Пенза, ул. Стасова, д. 8А </p></bio><bio xml:lang="en"><p>8A Stasov St., Penza, 440060</p></bio><email xlink:type="simple">epifanova.vrt@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Пензенский институт усовершенствования врачей — филиал ФГБОУ ДПО «Российская медицинская академия последипломного образования» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Penza Institute of Advanced Physician Training, a branch of the Russian Medical Academy of Continuing Professional Education (a Federal Government-funded Educational Institution of Advanced Professional Education), Russian Federation Ministry of Health</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Национальный исследовательский Мордовский государственный университет имени Н.П. Огарёва»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.P. Ogarev Mordovian National Research State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Пензенский государственный университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Penza State University (a Federal Government-funded Educational Institution of Higher Education)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>17</day><month>02</month><year>2025</year></pub-date><volume>21</volume><issue>1</issue><issue-title>ГИНЕКОЛОГИЯ</issue-title><fpage>54</fpage><lpage>58</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Виноградова О.П., Андреева Н.А., Артёмова О.И., Епифанова О.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Виноградова О.П., Андреева Н.А., Артёмова О.И., Епифанова О.В.</copyright-holder><copyright-holder xml:lang="en">Vinogradova O.P., Andreeva N.A., Artemova O.I., Epifanova O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://docru.elpub.ru/jour/article/view/141">https://docru.elpub.ru/jour/article/view/141</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: оценка эффективности применения противовирусного препарата при лечении ВПЧ-ассоциированной цервикальной интраэпителиальной неоплазии (cervical intraepithelial neoplasia, CIN) II степени на основании анализа уровней апоптотических маркеров и цитокинового профиля — каспаз 3 и 9, интерферона (ИФН) γ, интерлейкина (ИЛ) 18.</p></sec><sec><title>Дизайн</title><p>Дизайн: проспективное исследование.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследованы 126 женщин репродуктивного возраста. Были сформированы две группы: группа контроля, которая состояла из 40 относительно здоровых женщин фертильного возраста без заболеваний шейки матки и без ВПЧ, и группа из 86 женщин с CIN II, ассоциированной c ВПЧ. Проведено обследование всех участниц, у них оценивали цитокиновый ответ и уровни апоптотических маркеров. В группе CIN II всем пациенткам проведена эксцизия с иссечением пораженного участка. После нее 43 женщины находились под наблюдением (подгруппа А), а еще у 43 участниц хирургическое лечение проведено на фоне применения противовирусного препарата (подгруппа В). Препарат вводили подкожно с интервалом 1 день, 3 инъекции до проведения эксцизии и 3 после. Основными критериями эффективности лечения были отсутствие ВПЧ или уменьшение вирусной нагрузки ниже значимых величин, а также отсутствие рецидивирования патологического процесса через 6 и 12 месяцев исследования.</p></sec><sec><title>Результаты</title><p>Результаты. У участниц с CIN II содержание каспазы 3 и каспазы 9 до лечения оказалось значимо выше, чем в группе контроля, уровень ИФН-γ превышал показатель группы контроля в 1,8 раза, а средняя концентрация ИЛ-18 была существенно ниже (в обоих случаях p &lt; 0,05). В подгруппах А и В концентрации каспаз 3 и 9 через 3 и 6 месяцев после терапии также значимо отличались от таковых в группе контроля, при этом через 6 месяцев содержание каспаз 3 и 9 в подгруппе В было существенно ниже, чем в подгруппе А. У женщин подгрупп А и В прослеживалась статистически значимая разница в показателях цитокинового ряда: в обеих подгруппах концентрация ИФН-γ через 10 дней увеличилась, а через 12 месяцев снова приближалась к своим исходным значениям. Уровень ИЛ-18 в подгруппе В через 10 дней и 12 месяцев был существенно выше, чем в подгруппе А.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные данные свидетельствуют о высокой элиминации ВПЧ и снижении вероятности рецидива после эксцизионного лечения у пациенток с CIN II на фоне применения противовирусной терапии.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Study Objective</title><p>Study Objective: To assess the efficacy of an antiviral in the management of HPV-associated cervical stage II intraepithelial neoplasia (CIN II), using the analysis of the apoptotic marker levels and cytokine profile — caspase 3 and 9, interferon (INF) γ, interleukin (IL) 18.</p></sec><sec><title>Study Design</title><p>Study Design: Perspective study.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. We examined 126 women of reproductive age. The study included two groups: controls (40 relatively healthy fertile women without any cervical pathologies and HPV) and a group of 86 women with HPV-associated CIN II. All subjects underwent an examination; and their cytokine response and apoptotic marker level were assessed. All patients in CIN II group had the affect area excised. 43 post-excision women were followed up (sub-group A); other 43 subjects had surgery and an antiviral (sub-group B). The antiviral was administered subcutaneously once daily, 3 injections before and 3 injections after the excision. The primary efficacy criteria were absence of HPV or reduction in the viral load below significant values, and absence of pathology relapses after 6 and 12 months of the study.</p></sec><sec><title>Study Results</title><p>Study Results. In subjects with CIN II, pre-therapy caspase 3 and 9 levels were significantly higher vs controls; INF-γ was 1.8 times higher than in controls, and mean IL-18 concentration was considerably lower (p &lt; 0.05 in both cases). In sub-groups A and B, caspase 3 and 9 concentration in 3 and 6 months after therapy also differed significantly from controls, and in 6 months, caspase 3 and 9 concentration in sub-group В was considerably lower than in sub-group А. Women in sub-groups А and В demonstrated statistically significant difference in cytokine profile: in both sub-groups, INF-γ concentration in 10 days increased, while in 12 months it almost reached its baseline value. IL-18 in sub-group B in 10 days and 12 months was significantly higher than in sub-group А.</p></sec><sec><title>Conclusion</title><p>Conclusion. The results of the study demonstrate high HPV elimination and reduction in relapse probability after excision in patients with CIN II with the use of antivirals.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>вирус папилломы человека</kwd><kwd>цервикальная интраэпителиальная неоплазия</kwd><kwd>каспаза 3</kwd><kwd>каспаза 9</kwd><kwd>апоптоз</kwd><kwd>цитокины</kwd><kwd>интерлейкин 18</kwd><kwd>фактор некроза опухоли α</kwd><kwd>интерферон γ</kwd><kwd>рак шейки матки</kwd><kwd>генотипирование</kwd><kwd>высокий онкогенный риск</kwd></kwd-group><kwd-group xml:lang="en"><kwd>human papilloma virus</kwd><kwd>cervical intraepithelial neoplasia</kwd><kwd>caspase 3</kwd><kwd>caspase 9</kwd><kwd>apoptosis</kwd><kwd>cytokines</kwd><kwd>interleukin18</kwd><kwd>tumour necrosis factor α</kwd><kwd>interferon γ</kwd><kwd>cervical cancer</kwd><kwd>genetic typing</kwd><kwd>high risk of cancer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Shahida S.M., Lipi L.B., Rifat J.A. et al. Prevalence of cervical intraepithelial neoplasia in four Upazila of Dhaka division. Mymensingh Med. J. 2019; 28(3): 655–61.</mixed-citation><mixed-citation xml:lang="en">Shahida S.M., Lipi L.B., Rifat J.A. et al. Prevalence of cervical intraepithelial neoplasia in four Upazila of Dhaka division. Mymensingh Med. J. 2019; 28(3): 655–61.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rees C.P., Brhlikova P., Pollock A.M. Will HPV vaccination prevent cervical cancer? J. R. Soc. Med. 2020; 113(2): 64–78. DOI: 10.1177/0141076819899308</mixed-citation><mixed-citation xml:lang="en">Rees C.P., Brhlikova P., Pollock A.M. Will HPV vaccination prevent cervical cancer? J. R. Soc. Med. 2020; 113(2): 64–78. DOI: 10.1177/0141076819899308</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">He H., Pan Q., Pan J. et al. Study on the correlation between hTREC and HPV load and cervical CINI/II/III lesions and cervical cancer. J. Clin. Lab. Anal. 2020; 34(7): e23257. DOI: 10.1002/jcla.23257</mixed-citation><mixed-citation xml:lang="en">He H., Pan Q., Pan J. et al. Study on the correlation between hTREC and HPV load and cervical CINI/II/III lesions and cervical cancer. J. Clin. Lab. Anal. 2020; 34(7): e23257. DOI: 10.1002/jcla.23257</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Виноградова О.П., Артёмова О.И. Эффективность элиминации вируса папилломы человека при лечении патологии шейки матки. Доктор.Ру. 2020; 19(8): 80–5. DOI: 10.31550/1727-2378-2020-19-8-80-85</mixed-citation><mixed-citation xml:lang="en">Vinogradova O.P., Artemova O.I. The efficacy of human papillomavirus elimination during treatment of cervical disorders. Doctor.Ru. 2020; 19(8): 80–85. (in Russian). DOI: 10.31550/1727-2378-2020-19-8-80-85</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Епифанова О.В., Виноградова О.П., Андреева Н.А. Особенности консервативной иммунопротивовирусной терапии пациенток с ВПЧ-ассоциированными цервикальными интраэпителиальными неоплазиями I степени. Акушерство и гинекология. 2020; 3: 174–80. DOI: 10.18565/aig.2020.3.174-180</mixed-citation><mixed-citation xml:lang="en">Epifanova O.V., Vinogradova O.P., Andreeva N.A. Immune antiviral drug therapy in patients with HPV-associated cervical intraepithelial neoplasia grade I. Obstetrics and Gynegology. 2020; 3: 174–80. (in Russian). DOI: 10.18565/aig.2020.3.174-180</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sancakli Usta C., Altun E., Afsar S. et al. Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence. Infect. Agent Cancer. 2020; 15: 47. DOI: 10.1186/s13027-020-00312-9</mixed-citation><mixed-citation xml:lang="en">Sancakli Usta C., Altun E., Afsar S. et al. Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence. Infect. Agent Cancer. 2020; 15: 47. DOI: 10.1186/s13027-020-00312-9</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Van de Laar R.L.O., Hofhuis W., Duijnhoven R.G. et al. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. BMC Cancer. 2020; 20(1): 539. DOI: 10.1186/s12885-020-07025-7</mixed-citation><mixed-citation xml:lang="en">Van de Laar R.L.O., Hofhuis W., Duijnhoven R.G. et al. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. BMC Cancer. 2020; 20(1): 539. DOI: 10.1186/s12885-020-07025-7</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Полонская Н.Ю., Юрасова И.В. Цитологическое исследование цервикальных мазков. Пап-тест. М.: ГЭОТАР-Медиа, 2018. 168 с.</mixed-citation><mixed-citation xml:lang="en">Polonskaya N.Yu., Yurasova I.V. Cytologic screening of cervical smears. Pap Test. М.: GEOTAR-Media, 2018. 168 p. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ewaisha R., Panicker G., Maranian P. et al. Serum immune profiling for early detection of cervical disease. Theranostics. 2017; 7(16): 3814–23. DOI: 10.7150/thno.21098</mixed-citation><mixed-citation xml:lang="en">Ewaisha R., Panicker G., Maranian P. et al. Serum immune profiling for early detection of cervical disease. Theranostics. 2017; 7(16): 3814–23. DOI: 10.7150/thno.21098</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Skare T.L., Neppel A., Machoski M.C.C. et al. Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer. Immunol. Lett. 2019; 208: 8–10. DOI: 10.1016/j.imlet.2019.03.002</mixed-citation><mixed-citation xml:lang="en">Skare T.L., Neppel A., Machoski M.C.C. et al. Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer. Immunol. Lett. 2019; 208: 8–10. DOI: 10.1016/j.imlet.2019.03.002</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Barra F., Della Corte L., Noberasco G. et al. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. J. Obstet. Gynaecol. Res. 2020; 46(7): 989–1006. DOI: 10.1111/jog.14276</mixed-citation><mixed-citation xml:lang="en">Barra F., Della Corte L., Noberasco G. et al. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. J. Obstet. Gynaecol. Res. 2020; 46(7): 989–1006. DOI: 10.1111/jog.14276</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Villegas-Hinojosa E., Terán-Figueroa Y., Gallegos-García V. et al. Histopathological diagnosis of cervical biopsies: reduction of sampling errors with the evaluation of a third histologic level. Cancer Manag. Res. 2020; 12: 5099–104. DOI: 10.2147/CMAR.S225067</mixed-citation><mixed-citation xml:lang="en">Villegas-Hinojosa E., Terán-Figueroa Y., Gallegos-García V. et al. Histopathological diagnosis of cervical biopsies: reduction of sampling errors with the evaluation of a third histologic level. Cancer Manag. Res. 2020; 12: 5099–104. DOI: 10.2147/CMAR.S225067</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yin G., Li J., Wu A. et al. Four categories of LEEP for CIN of various areas: a retrospective cohort study. Minim. Invasive Ther. Allied Technol. 2017; 26(2): 104–10. DOI: 10.1080/13645706.2016.1236731</mixed-citation><mixed-citation xml:lang="en">Yin G., Li J., Wu A. et al. Four categories of LEEP for CIN of various areas: a retrospective cohort study. Minim. Invasive Ther. Allied Technol. 2017; 26(2): 104–10. DOI: 10.1080/13645706.2016.1236731</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Klügel S., Lücke C., Mehren A. et al. Patients with cervical intraepithelial neoplasms show different states of health-related quality of life and different coping styles depending on the choice of therapy: findings from the CIN study. Int. J. Womens Health. 2019; 11: 511–17. DOI: 10.2147/IJWH.S208257</mixed-citation><mixed-citation xml:lang="en">Klügel S., Lücke C., Mehren A. et al. Patients with cervical intraepithelial neoplasms show different states of health-related quality of life and different coping styles depending on the choice of therapy: findings from the CIN study. Int. J. Womens Health. 2019; 11: 511–17. DOI: 10.2147/IJWH.S208257</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Свидинская Е.А., Джибладзе Т.А., Зуев В.М. Роль определения молекулярно-генетических маркеров в диагностике и прогнозировании течения заболеваний шейки матки. Опухоли женской репродуктивной системы. 2010; 2: 93–8.</mixed-citation><mixed-citation xml:lang="en">Svidinskaya E.A., Dzhibladze T.A., Zuyev V.M. Role of determination of molecular genetic markers in the diagnosis and prediction of the course of cervix uteri diseases. Tumours of Female Reproductive System. 2010; 2: 93–8. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Трушина О.И., Новикова Е.Г., Шипулина О.Ю. и др. Вирусная нагрузка ДНК ВПЧ как прогностический фактор злокачественной прогрессии ПВИ. В кн.: Покровский В. И., ред. Молекулярная диагностика — 2014: сборник трудов VIII Всероссийской научно-практической конференции с международным участием. М.; 2014: 207.</mixed-citation><mixed-citation xml:lang="en">Trushina O.I., Novikova E.G., Shipulina O.Yu. et al. Viral load from HPV DNA as a predictive factor of malignant transformation of papilloma viral infection. In: Pokrovskiy V.I., eds. Molecular diagnosis — 2014: materials of the VIII All-Russian scientific and practical conference (with foreign participants). М.; 2014: 207. (in Russian)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
